What is the role of allogeneic bone marrow transplantation (BMT) or stem cell transplantation in the treatment of chronic myelogenous leukemia (CML)?

Updated: May 23, 2021
  • Author: Emmanuel C Besa, MD; Chief Editor: Sara J Grethlein, MD, FACP  more...
  • Print

Allogeneic bone marrow transplantation (BMT) or stem cell transplantation

  • Only proven cure for CML
  • Ideally performed in the chronic phase
  • Candidate patients should be offered the procedure if they have a matched or single–antigen-mismatched related donor available
  • Overall survival for allogeneic BMT with matched unrelated donors ranges from 31% to 43% for patients younger than 30 years and from 14% to 27% for older patients
  • Currently relegated to patients who do not achieve molecular remissions or show resistance to imatinib and failure of second-generation tyrosine kinase inhibitors (eg, dasatinib)
  • Patients with minimal residual disease after transplantation require interferon maintenance therapy or donor lymphocyte infusion

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!